Abstract

Malaria, a life-threatening blood disease, has been a major concern in the field of healthcare. One of the severe forms of malaria is caused by the parasite Plasmodium falciparum which is initiated through protein interactions of pathogen with the host proteins. It is essential to analyse the protein-protein interactions among the host and pathogen for better understanding of the process and characterizing specific molecular mechanisms involved in pathogen persistence and survival. In this study, a complete protein-protein interaction network of human host and Plasmodium falciparum has been generated by integration of the experimental data and computationally predicting interactions using the interolog method. The interacting proteins were filtered according to their biological significance and functional roles. α-tubulin was identified as a potential protein target and inhibitors were designed against it by modification of amiprophos methyl. Docking and binding affinity analysis showed two modified inhibitors exhibiting better docking scores of −10.5 kcal/mol and −10.43 kcal/mol and an improved binding affinity of −83.80 kJ/mol and −98.16 kJ/mol with the target. These inhibitors can further be tested and validated in vivo for their properties as an antimalarial drug.

Highlights

  • Malaria, one of the most distressing diseases, is caused by the parasitic protozoan Plasmodium falciparum

  • Malaria is highly prevalent in sub-Saharan Africa where 90% of all malaria deaths occur (WHO 2013)

  • There are a wide variety of antimalarial drugs, such as chloroquine and artemisinin, and strategies available for the control and treatment of malaria [1,2,3]

Read more

Summary

Introduction

One of the most distressing diseases, is caused by the parasitic protozoan Plasmodium falciparum. It takes away millions of lives with the rate increasing each growing year. According to WHO’s Factsheet on the World Malaria Report 2013, 1.2 billion people out of a total of an estimated 3.4 billion are at a high risk of malaria. Malaria is highly prevalent in sub-Saharan Africa where 90% of all malaria deaths occur (WHO 2013). A lot of research has been going on in the field of malarial therapeutics. There are a wide variety of antimalarial drugs, such as chloroquine and artemisinin, and strategies available for the control and treatment of malaria [1,2,3]

Objectives
Findings
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call